Ellipsis Health uses voice biomarkers to measure and manage mental health conditions such as stress, depression, and anxiety symptoms. The platform produces an assessment of a person’s mental health based on their speech, to support clinical decisions.
Key customers and partnerships
In August 2022, the company partnered with Ceras Health to use biomarkers derived from patients’ voices for mental health care on Ceras’ platform.
Funding and financials
In September 2021, Ellipsis raised USD 26 million in a Series A funding round to increase its membership base and global partnership, build a multifaceted team, research new voice-based solutions as well as build out its technology to tackle mental health for children and adolescents.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.